COVID-19 Vaccine Clinical Batches
COVID-19
ClinicalActive
Key Facts
About Advaxia Biologics
Advaxia Biologics is a private, revenue-generating CDMO focused on the development and manufacturing of adenovirus-based therapeutics and vaccines. The company leverages its state-of-the-art facility near Rome and a fully integrated service portfolio to support clients from preclinical stages through clinical supply, boasting a 100% batch approval rate. While its website emphasizes a services business model, the initial company data suggests an internal focus on immunology and oncology therapeutics, indicating a potential dual strategy of service provision and proprietary pipeline development, though the latter is not detailed publicly.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |